Press release
Bladder Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | AstraZeneca, Janssen R&D, Binhui Biopharma, Fidia Farmaceutici, RemeGen, IRCCS San Raffaele, SUNHO BioPharma
To Know in detail about the Bladder Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bladder Cancer Market Forecast
https://www.delveinsight.com/sample-request/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Bladder Cancer Market Report:
• The Bladder Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As per a study published in the American Cancer Society journal by Miller et al. (2022), there were approximately 789,730 individuals who survived urinary bladder cancer in the United States as of January 1, 2022, with an anticipated 81,180 new cases to be diagnosed in 2022. The prevalence of bladder cancer survivors is notably higher in men, as the incidence rate is approximately three times greater in men compared to women.
• As indicated by a report from the Spanish Society of Medical Oncology (2021), Spain had a total of 182,487 prevalent cases of bladder cancer.
• Key Bladder Cancer Companies: Guarionex J. Decastro, Merck Sharp & Dohme LLC, Janssen Research & Development, LLC, AstraZeneca, Janssen Research & Development, LLC, Binhui Biopharmaceutical Co., Ltd., Fidia Farmaceutici s.p.a, RemeGen Co., Ltd., IRCCS San Raffaele, SUNHO（China）BioPharmaceutical, Bristol-Myers Squibb, LintonPharm Co.,Ltd., Ferring Pharmaceuticals, Canadian Cancer Trials Group, UNICANCER, ImmunityBio, Inc., Kyoto University Hospital, and others
• Key Bladder Cancer Therapies: Cabazitaxel, Pembrolizumab, TAR-200, Durvalumab, TAR-200, OH2 injection, ONCOFID P-B (PACLITAXEL-HYALURONIC ACID), RC48-ADC, Nivolumab, IAP0971, Nivolumab, Catumaxomab, FE 999326, Durvalumab, Atezolizumab, N-803 and BCG, MK-3475, and others
• The Bladder Cancer epidemiology based on gender analyzed that the prevalence of bladder cancer is higher among males than females.
• The Bladder Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bladder Cancer pipeline products will significantly revolutionize the Bladder Cancer market dynamics.
Bladder Cancer Overview
Bladder cancer is a type of cancer that begins in the cells of the bladder, which stores urine. The most common type is urothelial carcinoma, which starts in the cells lining the inside of the bladder. Symptoms may include blood in the urine, frequent urination, pain during urination, and lower back pain. Risk factors include smoking, age, gender (more common in men), and exposure to certain chemicals. Treatment options typically include surgery, chemotherapy, radiation therapy, and immunotherapy, depending on the stage and grade of the cancer. Early detection is important for successful treatment outcomes.
Get a Free sample for the Bladder Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bladder Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Bladder Cancer Epidemiology Segmentation:
The Bladder Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Bladder Cancer
• Prevalent Cases of Bladder Cancer by severity
• Gender-specific Prevalence of Bladder Cancer
• Diagnosed Cases of Episodic and Chronic Bladder Cancer
Download the report to understand which factors are driving Bladder Cancer epidemiology trends @ Bladder Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bladder Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bladder Cancer market or expected to get launched during the study period. The analysis covers Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bladder Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Bladder Cancer Therapies and Key Companies
• Cabazitaxel: Guarionex J. Decastro
• Pembrolizumab: Merck Sharp & Dohme LLC
• TAR-200: Janssen Research & Development, LLC
• Durvalumab: AstraZeneca
• TAR-200: Janssen Research & Development, LLC
• OH2 injection: Binhui Biopharmaceutical Co., Ltd.
• ONCOFID P-B (PACLITAXEL-HYALURONIC ACID): Fidia Farmaceutici s.p.a
• RC48-ADC: RemeGen Co., Ltd.
• Nivolumab: IRCCS San Raffaele
• IAP0971: SUNHO（China）BioPharmaceutical
• Nivolumab: Bristol-Myers Squibb
• Catumaxomab: LintonPharm Co.,Ltd.
• FE 999326: Ferring Pharmaceuticals
• Durvalumab: Canadian Cancer Trials Group
• Atezolizumab: UNICANCER
• N-803 and BCG: ImmunityBio, Inc.
• MK-3475: Kyoto University Hospital
Discover more about therapies set to grab major Bladder Cancer market share @ Bladder Cancer Treatment Landscape
https://www.delveinsight.com/sample-request/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Bladder Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bladder Cancer Companies: Guarionex J. Decastro, Merck Sharp & Dohme LLC, Janssen Research & Development, LLC, AstraZeneca, Janssen Research & Development, LLC, Binhui Biopharmaceutical Co., Ltd., Fidia Farmaceutici s.p.a, RemeGen Co., Ltd., IRCCS San Raffaele, SUNHO（China）BioPharmaceutical, Bristol-Myers Squibb, LintonPharm Co.,Ltd., Ferring Pharmaceuticals, Canadian Cancer Trials Group, UNICANCER, ImmunityBio, Inc., Kyoto University Hospital, and others
• Key Bladder Cancer Therapies: Cabazitaxel, Pembrolizumab, TAR-200, Durvalumab, TAR-200, OH2 injection, ONCOFID P-B (PACLITAXEL-HYALURONIC ACID), RC48-ADC, Nivolumab, IAP0971, Nivolumab, Catumaxomab, FE 999326, Durvalumab, Atezolizumab, N-803 and BCG, MK-3475, and others
• Bladder Cancer Therapeutic Assessment: Bladder Cancer current marketed and Bladder Cancer emerging therapies
• Bladder Cancer Market Dynamics: Bladder Cancer market drivers and Bladder Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bladder Cancer Unmet Needs, KOL's views, Analyst's views, Bladder Cancer Market Access and Reimbursement
To know more about Bladder Cancer companies working in the treatment market, visit @ Bladder Cancer Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Bladder Cancer Market Report Introduction
2. Executive Summary for Bladder Cancer
3. SWOT analysis of Bladder Cancer
4. Bladder Cancer Patient Share (%) Overview at a Glance
5. Bladder Cancer Market Overview at a Glance
6. Bladder Cancer Disease Background and Overview
7. Bladder Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Bladder Cancer
9. Bladder Cancer Current Treatment and Medical Practices
10. Bladder Cancer Unmet Needs
11. Bladder Cancer Emerging Therapies
12. Bladder Cancer Market Outlook
13. Country-Wise Bladder Cancer Market Analysis (2019-2032)
14. Bladder Cancer Market Access and Reimbursement of Therapies
15. Bladder Cancer Market Drivers
16. Bladder Cancer Market Barriers
17. Bladder Cancer Appendix
18. Bladder Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Bladder Cancer Pipeline https://www.delveinsight.com/report-store/bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Bladder Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bladder Cancer market. A detailed picture of the Bladder Cancer pipeline landscape is provided, which includes the disease overview and Bladder Cancer treatment guidelines.
Bladder Cancer Epidemiology https://www.delveinsight.com/report-store/bladder-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Bladder Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Bladder Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Dry Eye Disease Market: https://www.delveinsight.com/report-store/dry-eye-disease-market-insights
• Nonalcoholic Steatohepatitis Market: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
• Female Infertility Market: https://www.delveinsight.com/report-store/female-infertility-market
• Gonorrhea Market: https://www.delveinsight.com/report-store/gonorrhea-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Structural Heart Devices Market: https://www.delveinsight.com/report-store/structural-heart-devices-market-market
• Prosthetic Heart Valve Market: https://www.delveinsight.com/report-store/prosthetic-heart-valve-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bladder Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | AstraZeneca, Janssen R&D, Binhui Biopharma, Fidia Farmaceutici, RemeGen, IRCCS San Raffaele, SUNHO BioPharma here
News-ID: 3795941 • Views: …
More Releases from DelveInsight Business Research
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
